Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411739 | 0.85 | EED (0.46) | SLC2A1GPR119EEDHTR1ASLC6A4 | |
| SCHEMBL6416993 | 0.82 | GPR119 (0.48) | GPR119HTR1ASLC6A4KDM4EPKM | |
| SCHEMBL26187444 | 0.82 | IDO1 (0.48) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL30648888 | 0.82 | IDO1 (0.48) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL16825188 | 0.82 | TGFBR1 (0.56) | SLC2A1EEDHTR1ASLC6A4KDM4E | |
| SCHEMBL13832786 | 0.81 | GPR119 (0.59) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL18970480 | 0.81 | GPR119 (0.59) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL13832725 | 0.81 | GPR119 (0.59) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL22266052 | 0.81 | SMN1; SMN2 (0.54) | GPR119KDM4EPKMJAK2JAK1 | |
| SCHEMBL11956986 | 0.81 | HTR1A (0.51) | SLC2A1GPR119HTR1ASLC6A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | SLC2A1 361/4885GPR119 279/4885EED 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.